Jazz Pharmaceuticals plc (JAZZ) stock
JAZZNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 2, 2026Score 7/30119% above fair value
$241.55+1.18 (+0.49%)
Close on Nov 13, 2026Market cap $15.68BP/E 78.7Yield –
Jazz Pharmaceuticals r&d expenses
Research and development expenses are spending on new products and technology.
Jazz Pharmaceuticals's R&D Expenses for the twelve months ending Sep 30, 2026 was $829.34M, up 2.5% year over year. For fiscal 2025 it was $782.74M, down 11.5% from the year before. Over ten years it grew 19.2% a year on average. The highest annual figure on record is $884.00M in fiscal 2024.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $782.74M | -11.5% |
| FY2024 | Dec 31, 2024 | $884.00M | +4.0% |
| FY2023 | Dec 31, 2023 | $849.66M | +43.9% |
| FY2022 | Dec 31, 2022 | $590.45M | +16.7% |
| FY2021 | Dec 31, 2021 | $505.75M | +50.8% |
| FY2020 | Dec 31, 2020 | $335.38M | +11.9% |
| FY2019 | Dec 31, 2019 | $299.73M | +32.3% |
| FY2018 | Dec 31, 2018 | $226.62M | +14.2% |
| FY2017 | Dec 31, 2017 | $198.44M | +22.3% |
| FY2016 | Dec 31, 2016 | $162.30M | +20.0% |
| FY2015 | Dec 31, 2015 | $135.25M | +58.8% |
| FY2014 | Dec 31, 2014 | $85.18M | +104.6% |
| FY2013 | Dec 31, 2013 | $41.63M | +103.3% |
| FY2012 | Dec 31, 2012 | $20.48M | +45.0% |
| FY2011 | Dec 31, 2011 | $14.12M | -44.9% |
| FY2010 | Dec 31, 2010 | $25.61M | -29.9% |
| FY2009 | Dec 31, 2009 | $36.56M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $211.90M | +6.9% |
| Q2 FY2026 | Jun 30, 2026 | $207.50M | +9.3% |
| Q1 FY2026 | Mar 31, 2026 | $196.00M | +8.5% |
| Q4 FY2025 | Dec 31, 2025 | $213.94M | -11.0% |
| Q3 FY2025 | Sep 30, 2025 | $198.20M | -0.9% |
| Q2 FY2025 | Jun 30, 2025 | $189.90M | -14.0% |
| Q1 FY2025 | Mar 31, 2025 | $180.70M | -18.9% |
| Q4 FY2024 | Dec 31, 2024 | $240.50M | +11.0% |
| Q3 FY2024 | Sep 30, 2024 | $199.92M | -14.7% |
| Q2 FY2024 | Jun 30, 2024 | $220.73M | +5.5% |
| Q1 FY2024 | Mar 31, 2024 | $222.85M | +17.7% |
| Q4 FY2023 | Dec 31, 2023 | $216.61M | +25.5% |
| Q3 FY2023 | Sep 30, 2023 | $234.40M | +57.5% |
| Q2 FY2023 | Jun 30, 2023 | $209.24M | +50.5% |
| Q1 FY2023 | Mar 31, 2023 | $189.41M | +45.7% |
| Q4 FY2022 | Dec 31, 2022 | $172.56M | +11.0% |
| Q3 FY2022 | Sep 30, 2022 | $148.87M | +5.6% |
| Q2 FY2022 | Jun 30, 2022 | $139.05M | +4.8% |
| Q1 FY2022 | Mar 31, 2022 | $129.98M | +69.7% |
| Q4 FY2021 | Dec 31, 2021 | $155.44M | +69.5% |
| Q3 FY2021 | Sep 30, 2021 | $141.04M | +79.3% |
| Q2 FY2021 | Jun 30, 2021 | $132.70M | +68.1% |
| Q1 FY2021 | Mar 31, 2021 | $76.57M | -11.1% |
| Q4 FY2020 | Dec 31, 2020 | $91.70M | -5.8% |
| Q3 FY2020 | Sep 30, 2020 | $78.65M | -1.5% |
| Q2 FY2020 | Jun 30, 2020 | $78.92M | +26.5% |
| Q1 FY2020 | Mar 31, 2020 | $86.11M | +43.3% |
| Q4 FY2019 | Dec 31, 2019 | $97.38M | +71.9% |
| Q3 FY2019 | Sep 30, 2019 | $79.86M | +56.1% |
| Q2 FY2019 | Jun 30, 2019 | $62.38M | +11.1% |
| Q1 FY2019 | Mar 31, 2019 | $60.11M | -4.1% |
| Q4 FY2018 | Dec 31, 2018 | $56.66M | -14.1% |
| Q3 FY2018 | Sep 30, 2018 | $51.16M | +8.0% |
| Q2 FY2018 | Jun 30, 2018 | $56.13M | +39.8% |
| Q1 FY2018 | Mar 31, 2018 | $62.67M | +39.5% |
| Q4 FY2017 | Dec 31, 2017 | $66.00M | +49.5% |
| Q3 FY2017 | Sep 30, 2017 | $47.36M | – |
| Q2 FY2017 | Jun 30, 2017 | $40.16M | – |
| Q1 FY2017 | Mar 31, 2017 | $44.93M | – |
| Q4 FY2016 | Dec 31, 2016 | $44.16M | – |
See a number that looks wrong?